Last reviewed · How we verify

Albuterol/salmeterol HFA MDI — Competitive Intelligence Brief

Albuterol/salmeterol HFA MDI (Albuterol/salmeterol HFA MDI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-2 adrenergic agonist combination (SABA/LABA). Area: Respiratory/Pulmonology.

phase 3 Beta-2 adrenergic agonist combination (SABA/LABA) Beta-2 adrenergic receptor Respiratory/Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Albuterol/salmeterol HFA MDI (Albuterol/salmeterol HFA MDI) — Teva Branded Pharmaceutical Products R&D, Inc.. Albuterol and salmeterol are beta-2 adrenergic agonists that relax airway smooth muscle to improve breathing, with albuterol providing rapid relief and salmeterol offering sustained bronchodilation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Albuterol/salmeterol HFA MDI TARGET Albuterol/salmeterol HFA MDI Teva Branded Pharmaceutical Products R&D, Inc. phase 3 Beta-2 adrenergic agonist combination (SABA/LABA) Beta-2 adrenergic receptor
Akovaz EPHEDRINE marketed Norepinephrine Releasing Agent Beta-2 adrenergic receptor 2016-01-01
Striverdi Respimat OLODATEROL Boehringer Ingelheim marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2014-01-01
Breo Ellipta VILANTEROL Glaxo Grp Ltd marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2013-01-01
Arcapta Neohaler INDACATEROL Novartis marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2011-01-01
Brovana ARFORMOTEROL Lupin marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2006-01-01
Foradil FORMOTEROL Novartis marketed beta2-Adrenergic Agonist Beta-2 adrenergic receptor 2001-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Beta-2 adrenergic agonist combination (SABA/LABA) class)

  1. Teva Branded Pharmaceutical Products R&D, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Albuterol/salmeterol HFA MDI — Competitive Intelligence Brief. https://druglandscape.com/ci/albuterol-salmeterol-hfa-mdi. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: